What is Diagnosys?
Diagnosys LLC is a specialized provider of visual function test systems, catering to both preclinical and clinical research needs. The company's core offerings include the Celeris® system, which features innovative dual-function stimulator-electrodes for enhanced rodent testing, alongside electroretinography solutions suitable for a range of animal sizes. Diagnosys serves a global clientele of researchers and clinicians from leading institutions, focusing on advancements in visual electrophysiology, psychophysical testing, and comprehensive trial services. With a legacy spanning over four decades, Diagnosys is dedicated to pushing the boundaries of visual function assessment through advanced technology and expert support.
How much funding has Diagnosys raised?
Diagnosys has raised a total of $506K across 2 funding rounds:
Debt
$150K
Debt
$356K
Debt (2020): $150K with participation from PPP
Debt (2021): $356K led by PPP
What's next for Diagnosys?
The substantial enterprise-level funding and recent strategic investment signal a period of accelerated growth and development for Diagnosys. This capital infusion is likely to fuel further innovation in their visual electrophysiology and psychophysical testing platforms, potentially expanding their market reach into new clinical applications or geographical regions. The company's focus on advanced technology and its established reputation suggest a strategic direction aimed at solidifying its leadership in the visual function assessment sector, possibly through enhanced product development, strategic partnerships, or expanded service offerings.
See full Diagnosys company page
